Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17030878 | 0.85 | MEN1 (0.44) | MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL25712271 | 0.82 | CYP2C9 (0.33) | MEN1ALDH1A1KMT2ACYP2C9 | |
| SCHEMBL19421178 | 0.79 | MEN1 (0.49) | MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL19421191 | 0.78 | ALDH1A1 (0.41) | MEN1ALDH1A1KMT2AMAPTCYP2C9 | |
| SCHEMBL21882563 | 0.77 | ALDH1A1 (0.53) | MEN1ALDH1A1KMT2AMAPTCYP2C9 | |
| SCHEMBL20976283 | 0.68 | MEN1 (0.35) | MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL13263379 | 0.68 | CYP2C9 (0.50) | MEN1ALDH1A1KMT2AMAPTCYP2C9 | |
| SCHEMBL10554603 | 0.68 | CYP2C9 (0.50) | MEN1ALDH1A1KMT2AMAPTCYP2C9 | |
| SCHEMBL17030773 | 0.68 | ALDH1A1 (0.50) | MEN1ALDH1A1KMT2AMAPT | |
| SCHEMBL10554599 | 0.68 | CYP2C9 (0.50) | MEN1ALDH1A1KMT2AMAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212170-A1 | INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF | ANTENGENE DISCOVERY LIMITED (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC (US) | 2023-05-11 | — | — | US | disclosed |
| US-11639346-B2 | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS | ARAXES PHARMA LLC (US) | 2023-05-02 | — | — | US | disclosed |
| US-20180155348-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2018-06-07 | — | — | US | disclosed |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-05-03 | — | — | US | disclosed |
| US-20180086753-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-03-29 | — | — | US | disclosed |
| US-20180015087-A1 | CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2018-01-18 | — | — | US | disclosed |
| US-9840516-B2 | Substituted quinazolines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-07-13 | — | — | US | disclosed |
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2017-01-26 | — | — | US | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | ARAXES PHARMA LLC | 2016-04-21 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180015087-A1 | CONJUGATES OF CEREBLON BINDING COMPOUNDS AND G12C MUTANT KRAS, HRAS OR NRAS PROTEIN MODULATING COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | MEN1 218/4885ALDH1A1 3952/4885KMT2A 1707/4885 |
| US-20180155348-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | MEN1 163/4885ALDH1A1 4028/4885KMT2A 1201/4885 |
| US-20160108019-A1 | INHIBITORS OF KRAS G12C MUTANT PROTEINS | KRAS, NRAS, HRAS | MEN1 102/4885ALDH1A1 3457/4885KMT2A 1188/4885 |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | MEN1 122/4885ALDH1A1 3753/4885KMT2A 1296/4885 |
| US-20230147053-A1 | FUSED N-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | MEN1 230/4885ALDH1A1 1402/4885KMT2A 2102/4885 |
| US-20180118757-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | MEN1 188/4885ALDH1A1 4009/4885KMT2A 736/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | MEN1 138/4885ALDH1A1 4178/4885KMT2A 850/4885 |
| US-11639346-B2 | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS | KRAS, NRAS, HRAS | MEN1 132/4885ALDH1A1 3346/4885KMT2A 718/4885 |
| US-20230212183-A9 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | MEN1 138/4885ALDH1A1 4178/4885KMT2A 850/4885 |
| US-20180086753-A1 | FUSED-TRICYCLIC INHIBITORS OF KRAS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | MEN1 208/4885ALDH1A1 2646/4885KMT2A 1005/4885 |
| US-20230212170-A1 | INHIBITORS OF KRAS G12C PROTEIN AND USES THEREOF | KRAS, NRAS, HRAS | MEN1 847/4885ALDH1A1 4502/4885KMT2A 3092/4885 |
| US-20170022184-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | MEN1 170/4885ALDH1A1 2059/4885KMT2A 1250/4885 |
| US-20170197945-A1 | 2-SUBSTITUTED QUINAZOLINE COMPOUNDS COMPRISING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | MEN1 103/4885ALDH1A1 3333/4885KMT2A 752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.